Evidence-based frameworks, epidemiological evaluations, and clinical management strategies developed by Dr. Haad Mahmood.
An Epidemiological Evaluation of U.S. Obesity Trends, GLP-1 Receptor Agonist Adoption, COVID-19 Mortality as a Catalyst, and the Rise of Health Awareness in America
Evaluates the hypothesis that GLP-1 receptor agonist adoption, pandemic-driven mortality awareness, and cultural health consciousness are contributing to a meaningful inflection in the U.S. obesity curve.
How Gut Dysbiosis, Intestinal Permeability, LPS Translocation, and Endotoxemia Drive Systemic Inflammation and Insulin Resistance
Presents the complete mechanistic pathway from gut barrier disruption through LPS translocation, immune activation, and systemic inflammation, outlining evidence-based strategies for restoring gut barrier integrity.
Cytokine-Mediated IRS-1 Dysfunction, PI3K/Akt Pathway Inhibition, and the Molecular Basis of Metabolic Treatment Resistance
Examines how chronic low-grade inflammation acts as a central driver of insulin resistance, detailing the molecular pathway from inflammatory cytokine release to cellular metabolic dysfunction across key tissues.
The 80/20 Framework: Why Lifestyle Modifications Determine Success or Failure in GLP-1 Receptor Agonist Therapy
Introduces the 80/20 Framework, demonstrating why medication management is only a fraction of therapeutic success, and detailing how resistance exercise and muscle mass preservation determine long-term metabolic outcomes.
HPA Axis Dysregulation, Thyroid Pathway Interference, and Clinical Management Strategies
Provides a clinical framework for understanding cortisol dysfunction across three phases, examining the mechanistic relationship between chronic stress, thyroid pathway interference, and treatment resistance.

© Copyright 2026. HaadMD. All Rights Reserved.